Multiple sclerosis

Relapsing-remitting or secondary progressive multiple sclerosis that is clinically or radiologically active

Therapy: The investigational drug is a highly selective reversible inhibitor of Bruton’s tyrosine kinase (BTK). It has been approved for the treatment of mantle cell lymphoma and has also shown efficacy in treating B-cell-derived hematological malignancies in patients who have previously received older BTK inhibitors.

Why participate in the study:

  • Better tolerability is expected for the innovative therapy due to its specific mechanism of action.
  • Regular brain MRIs will be performed on patients to monitor the effectiveness of the therapy.
  • Opportunity for treatment with the innovative therapy, which is expected to have better tolerability than other BTK inhibitors, due to its specific mechanism of action.
  • Continuous monitoring by top neurologist physicians and an experienced study team.
  • The innovative therapy is free of charge and administered orally in tablet form.

From what date can you participate? September 2023.


Receive regular notifications about our activities and news in treatments.

Free examinations